MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

41.78 -0.11 (-0.26%)
Streaming Delayed Price Updated: 1:40 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,618
Open 41.87
Bid (Size) 41.65 (100)
Ask (Size) 41.84 (200)
Prev. Close 41.89
Today's Range 41.67 - 41.99
52wk Range 22.29 - 42.81
Shares Outstanding 11,782,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+49.3%
+49.3%
1 Month
+13.7%
+13.7%
3 Month
+76.7%
+76.7%
6 Month
+24.8%
+24.8%
1 Year
+68.5%
+68.5%

More News

Read More
News headline image
Halper Sadeh LLC is Investigating Whether XOMA, RMAX, GRTX are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Royalty Corporation (NASDAQ:XOMA) Passes Key Growth and Momentum Filters ↗
Via Chartmill
XOMA Royalty Corporation (NASDAQ:XOMA) Passes Strict "Little Book" Growth Stock Screen ↗
Via Chartmill
XOMA Royalty Corporation (NASDAQ:XOMA) Beats Q4 2025 Earnings Estimates, Stock Rises ↗
Via Chartmill
News headline image
XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead ↗
Via Benzinga
News headline image
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data ↗
Via The Motley Fool
Topics Stocks
News headline image
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
XOMA Royalty Announces CFO Transition
From XOMA Royalty Corporation
Via GlobeNewswire
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Common Stock publicly traded?
Yes, XOMA Royalty Corporation - Common Stock is publicly traded.
What exchange does XOMA Royalty Corporation - Common Stock trade on?
XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Common Stock?
The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Common Stock?
The current price of XOMA Royalty Corporation - Common Stock is 41.78
When was XOMA Royalty Corporation - Common Stock last traded?
The last trade of XOMA Royalty Corporation - Common Stock was at 05/11/26 01:40 PM ET
What is the market capitalization of XOMA Royalty Corporation - Common Stock?
The market capitalization of XOMA Royalty Corporation - Common Stock is 492.28M
How many shares of XOMA Royalty Corporation - Common Stock are outstanding?
XOMA Royalty Corporation - Common Stock has 492M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story